Novel Drug Review of Approved 2020 Breast Cancer Agents
Oscar E. Freyre
Abstract
Annually, The Food and Drug Administration’s Center for Drug Evaluation and Research publishes a report containing the latest drugs approved. In this review, the following breast cancer agents; Cerianna™ (fluoroestradiol F-18), Trodelvy (sacituzumab govitecan-hziy), and Tukysa (tucatinib), are evaluated for their drug properties including dosing and administration, absorption, distribution, metabolism, excretion, and adverse effects & warnings. In addition to their pharmacological parameters, review of the National Comprehensive Cancer Network (NCCN) Breast Cancer clinical guidelines assess how these agents may impact current clinical practice.
Full Text
volume5article2.pdf
File Size: 418 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH